Janus Henderson Group PLC Buys New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Janus Henderson Group PLC bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 1,188,191 shares of the company's stock, valued at approximately $30,329,000. Janus Henderson Group PLC owned approximately 2.30% of Bicara Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $229,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $462,000. The Manufacturers Life Insurance Company bought a new position in Bicara Therapeutics in the 3rd quarter valued at $582,000. Walleye Capital LLC acquired a new position in Bicara Therapeutics in the third quarter worth $809,000. Finally, Vestal Point Capital LP bought a new stake in shares of Bicara Therapeutics during the third quarter worth $10,825,000.

Analysts Set New Price Targets

BCAX has been the subject of a number of research analyst reports. Rodman & Renshaw began coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price target for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating for the company. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective on the stock. Finally, TD Cowen started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $43.00.

Bicara Therapeutics Price Performance

Shares of BCAX traded up $1.56 on Friday, reaching $21.10. 307,299 shares of the company's stock were exchanged, compared to its average volume of 293,732. The stock's 50 day simple moving average is $21.73. Bicara Therapeutics Inc. has a 12 month low of $17.41 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, analysts expect that Bicara Therapeutics Inc. will post -2.89 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the business's stock in a transaction dated Monday, September 16th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now directly owns 4,303,418 shares of the company's stock, valued at approximately $77,461,524. This trade represents a 74.20 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn bought 70,000 shares of the company's stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.